Navigation Links
VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
Date:3/31/2009

n risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

    Factors that may cause actual results to differ materially from current
    expectations include, but are not limited to:
      -- our ability to borrow additional amounts under the loan from Bay
         City Capital, which is subject to the discretion of Bay City
         Capital;
      -- our ability to obtain necessary financing in the near term,
         including amounts necessary to repay the loan from Bay City Capital
         by the September 14, 2009 maturity date (or earlier if certain
         repayment acceleration provisions are triggered);
      -- our ability to control our operating expenses;
      -- our ability to comply with covenants included in the loan from Bay
         City Capital;
      -- our failure to timely recruit and enroll patients for the FDG-PET
         clinical trial, as well as any future clinical trial;
      -- our failure to obtain sufficient data from enrolled patients that
         can be used to evaluate VIA-2291, thereby impairing the validity or
         statistical significance of our clinical trials;
      -- our ability to successfully complete our clinical trials of VIA-2291
         on expected timetables and the outcomes of such clinical trials;
      -- complexities in designing and implementing cardiovascular clinical
         trials using histological examinations, measurement of biomarkers,
         medical imaging and atherosclerotic plaque bioassays;
      -- the results of our clinical trials, including without limitation,
         with respect to the safety and efficacy of VIA-2291;
      -- if the results of the ACS and CEA studies, upon further review and
         analysis, are revised or negated by authorities or by later stage
         clinical trials;
      -- our ab
'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... MacroGenics, Inc. announced today that Mr. Paulo F. Costa has ... Mr. Costa is the former President and Chief Executive ... years of experience in operations and commercialization in the pharmaceutical ... , , "We are privileged to have Mr. Costa ...
... VIENNA, Austria, June 23 MIG Fonds and AFFiRiS ... Private Equity Award,competition, hosted by the industry magazine Boerse-Express and ... fund and the Austrian biotechnology company as well as a ... Last Tuesday MIG Fonds and AFFiRiS AG ...
... Denosumab Data , , THOUSAND OAKS, Calif., June 22 ... announced that the U.S. Food and Drug Administration (FDA) has ... Reproductive Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. ... (BLA) for denosumab, a RANK Ligand inhibitor for which Amgen ...
Cached Biology Technology:Paulo F. Costa Joins MacroGenics Board of Directors 2Paulo F. Costa Joins MacroGenics Board of Directors 3AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 2Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 3Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 4Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 5Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 6Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 7
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... could benefit from drinking diet soda. New research from ... citrate and malate content in commonly consumed sodas may ... The study was presented at the 104th Annual Scientific ... Increased alkalinity is proven to augment citraturia, a known ...
... a novel approach for thwarting the relentless bacterial infections ... fibrosis (CF), unlocking new possibilities against a tenacious and ... a mainstay antibiotic with drugs to deprive the bacteria ... boost infection killing, they found. Their research, reported ...
... has a soundtrack. Its tempo and tone will vary, ... the brain itself. When that soundtrack is recorded and ... -- it may sharpen their reflexes during a crisis, and ... influence of music on cognitive development, learning, and emotional well-being ...
Cached Biology News:Two-pronged model could help foil tough cystic fibrosis infections 2Two-pronged model could help foil tough cystic fibrosis infections 3Brain music 2
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
...
Biology Products: